Posts

Showing posts from February, 2019

Medicinal Mushrooms: Turkey Tail (Trametes versicolor), Reishi (Ganoderma lucidum) and Lion's mane (Hericium erinaceus)

Image
There some evidence in PubMed than medicinal mushrooms may play a role in treatment of some cancers. Most of the claims of medical benefits are bot backed up by high quality studies as of 2019. References are below. --- What is turkey tail? Turkey tail is a type of mushroom that grows on dead logs worldwide. It's named turkey tail because its rings of brown and tan look like the tail feathers of a turkey. Its scientific name is Trametes versicolor or Coriolus versicolor. In traditional Chinese medicine, it is known as Yun Zhi. In Japan, it is known as kawaratake (roof tile fungus). Turkey tail has been used in traditional Chinese medicine to treat lung diseases for many years. In Japan, turkey tail has been used to strengthen the immune system when given with standard cancer treatment. What is PSK? Polysaccharide K (PSK) is the best known active compound in turkey tail mushrooms. In Japan, PSK is an approved mushroom product used to treat cancer. How is PSK given or taken? PSK can

New Treatment for Acquired Thrombotic Thrombocytopenic Purpura: Caplacizumab

Image
Immune-mediated deficiency of the von Willebrand factor–cleaving protease ADAMTS13 allows unrestrained adhesion of von Willebrand factor multimers to platelets and microthrombosis. This results in thrombocytopenia, hemolytic anemia, and tissue ischemia. These are the hallmarks of  acquired thrombotic thrombocytopenic purpura (TTP). Caplacizumab is an anti–von Willebrand factor humanized. Caplacizumab is not a full antibody, but just a fragment if it, as you can see in the video below. It inhibits interaction between von Willebrand factor multimers and platelets. In this double-blind, controlled trial, 145 patients with TTP received caplacizumab (10-mg intravenous loading bolus, followed by 10 mg daily subcutaneously) or placebo during plasma exchange and for 30 days thereafter. The median time to normalization of the platelet count was shorter with caplacizumab than with placebo (2.69 days vs. 2.88 days). Patients who received caplacizumab were 1.55 times as likely to have a normalizat